iiinova — where your digital self keeps evolving

JAMA Neurology @jamaneurology.com · 01/10/2026

Can anesthesia choice during #stroketreatment affect recovery? #sedation #anesthesia 📌 Learn more: ja.ma/4hHLMll

JAMA Neurology @jamaneurology.com · 21/09/2026

📝 The #HINTS examination is most effective in patients with continuous dizziness and spontaneous nystagmus at rest. This Review indicates that outside this population , HINTS can reduce stroke diagnostic accuracy and lead to unnecessary imaging. ja.ma/4xDD7VV

Clinical decision algorithm for acute-onset persistent dizziness. It screens for central features, then horizontal nystagmus at rest, and assesses gait. Key outcomes are workup for acute stroke, peripheral cause (vestibular neuritis), or HINTS suggesting central cause.

000

JAMA Neurology @jamaneurology.com · 21/09/2026

📊🧠 A harmonized #TauPET visual reading framework for #AlzheimerDisease with five classes showed high agreement across raters and tracers, and identified more early-stage tau pathology than the regulatory-approved binary approach. ja.ma/4hiNHLV

Brain anatomy with multi-colored masks in superior, inferior, lateral, and medial views. A table shows Harmonized tau PET visual read classification criteria from Negative to Atypical. Three PET brain scans (Sagittal, Coronal, Axial) display brain activity using a red-blue-green color scale.

000

JAMA Neurology @jamaneurology.com · 14/09/2026

📝 #Review from @jama.com: #Idiopathic normal pressure hydrocephalus is a progressive neurologic disorder in older adults associated with gait impairment and often urinary dysfunction and cognitive decline. 🔗 Learn more: ja.ma/3Tuhut6

Diagram illustrating Idiopathic Normal Pressure Hydrocephalus (iNPH) pathophysiology from JAMA. It details mechanisms like altered CSF dynamics, increased pulsatility, elevated venous pressure reducing CSF drainage, and CSF accumulation causing ventriculomegaly and brain compression.

000

JAMA Neurology @jamaneurology.com · 06/09/2026

Among patients with #BranchAtheromatousDisease-related #IschemicStroke, intravenous #Tirofiban plus aspirin did not reduce early neurological deterioration or new stroke compared with aspirin alone. ja.ma/4cYrWQ8

JAMA Neurology RCT on Tirofiban+aspirin vs. placebo+aspirin for stroke. 970 patients (607M, 363F, median 63y) in China. Findings: No significant difference in early neurological deterioration or new stroke incidence between groups. Graph shows similar cumulative incidence for both (HR 0.88, P=.39).

000

JAMA Neurology @jamaneurology.com · 06/09/2026

💬 Editorial: Among patients with #BranchAtheromatousDisease-related #IschemicStroke, the trial did not show an overall benefit of tirofiban plus aspirin. ja.ma/3UDTDrh

JAMA Neurology Editorial: 'Tirofiban for Branch Atheromatous Disease—End of the Line or New Opportunity?' authored by Dixon Yang, S. Andrew Josephson, and Hooman Kamel. Published online August 31, 2026.

000

JAMA Neurology @jamaneurology.com · 26/08/2026

In 2 clinical trials, once-daily #tevapadon improved symptoms in patients with #ParkinsonDisease, increasing daily good on time in those taking levodopa and improving motor scores in early disease vs placebo. 📖 Read the full article to learn more: ja.ma/4xfuYYw

000

JAMA Neurology @jamaneurology.com · 24/08/2026

Female sex, smoking, and family history were independent risk factors for de novo #IntracranialAneurysm formation after #AneurysmalSubarachnoidHemorrhage, and #SmokingCessation was associated with lower risk. ja.ma/3Uwn12r

Graph showing Cumulative Incidence of De Novo Intracranial Aneurysm Formation over 50 years. Two curves, "Cumulative incidence function" (blue) and "Kaplan-Meier" (orange), both rise. Kaplan-Meier is higher, reaching ~50% at 50 years, while the blue curve reaches ~35%. Numbers at risk decrease from 544 to 11.

010

JAMA Neurology @jamaneurology.com · 20/08/2026

For most patients with stroke and nonvalvular atrial fibrillation, anticoagulants alone remain the recommended treatment to prevent recurrence. Added therapies, like #aspirin or catheter ablation, may not provide benefit. #StrokePrevention 📖 Read full article to learn more: ja.ma/4zhyJxR

000

JAMA Neurology @jamaneurology.com · 17/08/2026

Among patients with idiopathic #Myelopathy, screening for anti-CD320 antibodies with metabolic confirmation of central nervous system–restricted #VitaminB12 deficiency may help clarify diagnosis and guide treatment evaluation. ja.ma/4ic7a2O

Figure 3: Dorsolateral MRI scans of cervical & thoracic spine (sagittal & axial T2 views) from Participants 19, 31, & 13. Shows abnormalities in Idiopathic Myelopathy with positive Anti-CD320. Orange lines show axial slice levels; Participant 13 has pre/posttreatment scans.

010

JAMA Neurology @jamaneurology.com · 17/08/2026

Among adults with #Epilepsy receiving direct oral anticoagulants, antiseizure medication selection was associated with different risks of thromboembolic events, major bleeding, and all-cause mortality. ja.ma/4x3Dc5E

Four forest plots show HRs for antiseizure medicines (ASMs) vs Lamotrigine/Lacosamide. Levetiracetam is linked to higher thromboembolic events & all-cause mortality. Valproate shows higher all-cause mortality. Strong EI shows lower bleeding events.

000

JAMA Neurology @jamaneurology.com · 15/08/2026

Among veterans with prior #TraumaticBrainInjury, the plasma p-tau217/Aβ42 blood test for #AlzheimerDisease missed over half of brain amyloid-positive cases, indicating reduced diagnostic accuracy in this population. ja.ma/4x3cf2f

Three box-and-whisker plots illustrate biomarkers' Amyloid-β (Aβ) discrimination by Aβ-PET positivity and TBI group. Plots show p-tau217/Aβ42, p-Tau217, and Aβ42/Aβ40 ratios. Significant differences (P<.002) are observed between Aβ- and Aβ+ groups across TBI severities.

121

JAMA Neurology @jamaneurology.com · 13/08/2026

Among adult #Ebola survivors, neurological symptoms such as memory loss, headaches, and depression remained common even 7 years post-infection, although most improved over time. ja.ma/4wRcoWd

JAMA Neurology article: Neurological Manifestations in Adult Survivors Ebola Virus Disease. Four line graphs show General Neurological Examination (GNE) and Central Nervous System (CNS) scores over 0-100 months post-EVD. Data for survivors & contacts, split by age <40 & ≥40. Scores generally decrease over time.

143

JAMA Neurology @jamaneurology.com · 12/08/2026

Machine learning analysis of patient-clinician conversations identified cognitive impairment with sensitivity 68% and specificity 64%, supporting passive speech-based screening in routine #PrimaryCare. ja.ma/4xBpjvE

Workflow diagram showing acoustic noise, patient, and physician speech combining into raw recordings. These are windowed into 30-second segments, processed for whisper features, then fed into XGBoost for segment-level and aggregated recording-level predictions. Two distinct data flows are shown.

002

JAMA Neurology @jamaneurology.com · 10/08/2026

Among amyloid-positive individuals, a 7-protein plasma panel improved identification of advanced neocortical #tau pathology compared with phosphorylated tau-217 alone. ja.ma/4zowKbl

Figure 3 shows five graphs comparing the performance of the Elastic Net (EN) Panel and p-Tau217 for identifying late Braak individuals. The EN panel consistently demonstrates superior or comparable performance across ROC curves, specificity, sensitivity, PPV, and NPV compared to p-Tau217.

010

JAMA Neurology @jamaneurology.com · 10/08/2026

In generalized #MyastheniaGravis, inebilizumab was associated with fewer exacerbations during corticosteroid tapering, including less use of intravenous immunoglobulin or plasma exchange. ja.ma/4q2AY3Q

Bar chart: Participants with exacerbation (%). Inebilizumab (orange bars) consistently shows lower percentages than Placebo (gray bars) across all groups. Combined: Placebo ~35%, Inebilizumab ~15%. AChR+: Placebo ~32%, Inebilizumab ~17%. MuSK+: Placebo ~45%, Inebilizumab ~12%. Inebilizumab reduces exacerbation risk.

000

JAMA Neurology @jamaneurology.com · 08/08/2026

In #PrimaryProgressiveAphasia, automated #SpeechAnalysis of a brief picture description task distinguished nonfluent, logopenic, and semantic variants and produced interpretable speech profiles. ja.ma/4wRIH7y

Figure 1: Multinomial Speech Profiles for Primary Progressive Aphasia (PPA) Variants. A 3D scatterplot shows nfvPPA, lvPPA, and svPPA data points clustered and separated by planes. B, C, D are confusion matrices for clinical, external, and neuropathological validation, detailing predicted vs. actual diagnoses/pathologies.

000

JAMA Neurology @jamaneurology.com · 08/08/2026

In #MultipleSclerosis, higher serum glial fibrillary acidic protein was associated with greater risk of progression independent of relapse activity, while neurofilament light chain was more closely associated with relapse risk. ja.ma/3SlEudh

Two Kaplan-Meier curves on Progression Independent of Relapse Activity (PIRA) over time. Both the Swiss MS and EPIC MS cohorts show a higher proportion of PIRA in the GFAP z score > 1 group (orange line) compared to the GFAP z score ≤ 1 group (teal line).

000

JAMA Neurology @jamaneurology.com · 03/08/2026

This case report describes a 60-year-old woman presenting with sudden loss of muscle tone with preserved consciousness and severe daytime sleepiness. ja.ma/4fMpmgB

JAMA Neurology article page titled: Global and Partial Cataplexy, Geste Antagoniste, and Startle Response in Narcolepsy Type 1. Authored by Roberta Di Giacomo, Lorella Pesce, and Giuseppe Didato. Published online August 3, 2026.

010

JAMA Neurology @jamaneurology.com · 03/08/2026

Figure 1: Multinomial Speech Profiles for Primary Progressive Aphasia Variants. A 3D scatterplot shows nfvPPA (orange), lvPPA (dark teal), and svPPA (light teal) data points forming distinct clusters. Three confusion matrices display classification accuracy for clinical diagnoses and underlying neuropathologies.

011

JAMA Neurology @jamaneurology.com · 03/08/2026

Kaplan-Meier curves for two MS cohorts (Swiss & EPIC) show time to progression independent of relapse activity (PIRA) based on GFAP z scores. Both graphs indicate that patients with GFAP z score > 1 (orange line) have a higher proportion of PIRA over time compared to those with GFAP z score ≤ 1 (blue line).

011

JAMA Neurology @jamaneurology.com · 03/08/2026

JAMA Neurology EIC S. Andrew Josephson, MD, selected this as his 2025 Editor's Choice: Clinical Trial of the Year for its important findings on relapse risk after discontinuing disease-modifying therapy in stable MS. 🔗 Read the Editorial: ja.ma/3S5wbSN

161

JAMA Neurology @jamaneurology.com · 03/08/2026

In a RCT published in JAMA Neurology, stopping first-line disease-modifying therapy led to more inflammatory disease activity vs continuing treatment for patients with stable #MultipleSclerosis (MS) for at least 5 years. ja.ma/3TOFkzx

164

JAMA Neurology @jamaneurology.com · 03/08/2026

Patients with functional #neurological disorder exhibit frequent psychiatric and neurological comorbidities, worse functional outcomes, higher health care use, and increased mortality compared with multiple sclerosis. ja.ma/3Rvrq4N

Figure 1. Bar chart: 'Distribution of diagnoses by sex'. Y-axis: No. of patients (0-60k). X-axis: Diagnosis (FND-motor, FND-seizure, FND-sensory, FND-mixed). Females (grey) show notably higher patient numbers than Males (orange) across all diagnoses. Unknown (light blue) are low.

175

JAMA Neurology @jamaneurology.com · 27/07/2026

Limiting #ParkinsonDisease genetic testing to onset ≤50 years misses most carriers of pathogenic variants, including many eligible for gene-targeted therapies; broader, age-inclusive strategies may improve diagnostic yield. ja.ma/3RXVm9J

Bar graph titled 'Age Bracket Performance of AAO Criteria for Genetic Testing in Parkinson Disease (PD)'. PPV on Y-axis, Age at onset on X-axis. It compares ROPAD (dark gray) and PD GENEration (blue). PD GENEration peaks at ~0.5 for age <30 & generally decreases with age. ROPAD is lower, showing a similar trend.

000

JAMA Neurology @jamaneurology.com · 16/07/2026

#Dementia prevalence increased over 2 decades in Mexico, Peru, and Puerto Rico, while rates remained stable in Cuba and the Dominican Republic, indicating an uneven and rising burden compared with high-income countries. ja.ma/4heaiuy

JAMA Neurology: "Trends in Dementia Prevalence Across Latin America and the Caribbean" (July 13, 2026). Bar graph compares age/sex-standardized dementia prevalence (2003-06 vs. 2016-20) in Cuba, Dominican Republic, Peru, Mexico, Puerto Rico. Most countries show increases; Puerto Rico highest, Cuba slightly decreased.

000

JAMA Neurology @jamaneurology.com · 13/07/2026

📑 JAMA Neurology #Review: Gene delivery platforms for #Glioblastoma include viral vectors, lipid nanoparticles, and nanocarriers, with oncolytic HSV gaining approval and new nonviral approaches entering early clinical trials in #NeuroOncology. ja.ma/4bomipD

Diagram. A: Iterative R&D feedback loop: computational modeling, platform dev, window-of-opportunity trials, go/no-go decision, advanced clinical trials. B: 5 layers of glioblastoma gene therapy specificity: Administrative, Cell entry, Transcriptional, Posttranscriptional, Functional. C: Innovations: Long-term catheters, Synthetic biology, Combinatorial strategies.

031

JAMA Neurology @jamaneurology.com · 13/07/2026

Presented today at #AAIC26: #Dementia prevalence increased over 2 decades in Mexico, Peru, and Puerto Rico, while rates remained stable in Cuba and the Dominican Republic, indicating an uneven and rising burden compared with high-income countries. ja.ma/4fxCuaw

JAMA Neurology graph: 'Trends in Dementia Prevalence Across Latin America and the Caribbean'. Bar graph shows age- & sex-standardized dementia prevalence (2003-2006 vs. 2016-2020) in 5 countries. Prevalence increased in Peru, Mexico, and Puerto Rico, while slightly decreasing in Cuba and Dominican Republic.

000

JAMA Neurology @jamaneurology.com · 12/07/2026

Presented at #AAIC26 from @JAMA.com: #Amyloid clearance was most efficient in gyral crests, not sulcal depths, and correlated locally with reduced #tau #pathology and #neurodegeneration after aducanumab therapy in #AlzheimerDisease. ja.ma/3SYsxtZ

JAMA Figure 2: Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease. Panels A-C display beta-amyloid plaques & clearance in brain tissue; D-F show phosphorylated tau pathology, reactive microglia & astrocytes at various magnifications. Published July 12, 2026.

000

JAMA Neurology @jamaneurology.com · 02/07/2026

This case report describes a 71-year-old woman presenting with altered speech, gait difficulties, and hearing loss diagnosed with infratentorial superficial siderosis and a thoracic spinal cord cleft. ja.ma/4vKlSlR

Figure 1. Clinical Imaging of a Spinal Cord Cleft. A) Axial T2-weighted MRI shows a bright C-shaped spinal canal with a pink arrow pointing to a dark cleft within. B) Intraoperative ultrasound shows complex internal spinal structures with a pink arrow pointing to an anomaly.

000

JAMA Neurology @jamaneurology.com · 02/07/2026

Three box plots show biomarker discrimination by Aβ-PET positivity (Aβ+/Aβ-) and TBI group. (A) p-tau217/Aβ42, (B) p-Tau217, (C) Aβ42/Aβ40. All are log scales. X-axis groups: None, LOC 0-5 min, LOC >5 min, each split by Aβ-/Aβ+. P-values often <.001, indicating significant differences.

000

JAMA Neurology @jamaneurology.com · 23/06/2026

A patient with isolated peripheral nerve vasculitis developed reversible bilateral hypoglossal palsy and tongue atrophy, with resolution of bulbar symptoms following immunosuppressive therapy and reinnervation, a rare neurological outcome. ja.ma/3SVI9yg

Figure 1: Tongue Appearance Before & After Treatment. A: Atrophied tongue at presentation, showing pale, coated surface. B: Resolution of atrophy, displaying a pinker, healthier tongue.

010

JAMA Neurology @jamaneurology.com · 22/06/2026

💬 Perspective from JAMA: Monoclonal antibodies for #AlzheimerDisease clear brain amyloid-β and modestly slow cognitive decline in early stages, supporting a causal role but with clinically limited impact and risk for imaging abnormalities. ja.ma/4acXv7D

JAMA academic article titled 'Stopping Alzheimer Disease 50 Years of Progress' by John K. Hsiao, MD. Published online June 22, 2026. A 'PERSPECTIVE' piece, the page is filled with dense text discussing the history and research on Alzheimer's disease.

010

JAMA Neurology @jamaneurology.com · 22/06/2026

Among patients with familial or sporadic #Frontotemporal #Dementia, cerebrospinal fluid TMEM106B levels were lower with greater disease severity, progression, smaller brain volumes, and in carriers of the protective rs1990622 genotype. ja.ma/3SzcpPm

Four scatter plots show standardized frontotemporal volume vs CSF markers. TMEM106B positively correlates (β>0, P≤.002) and NFL negatively correlates (β<0, P≤.02) with volume across discovery and validation cohorts.

010

JAMA Neurology @jamaneurology.com · 22/06/2026

Diagram of an acoustic processing pipeline. Inputs (Acoustic noise, Patient/Physician speech) lead to Raw recording, then 30-sec window recordings, and Segment-level whisper features. These feed into XGBoost for Segment-level prediction, aggregated to Recording-level prediction.

000

JAMA Neurology @jamaneurology.com · 20/06/2026

000

JAMA Neurology @jamaneurology.com · 19/06/2026

💬 Editorial: Routine clinical conversations in #PrimaryCare contain acoustic signals that machine learning models can use for passive cognitive impairment screening, but risks and potential biases must be evaluated before clinical adoption. ja.ma/4ePVXTw

JAMA Neurology editorial: "Clinical Conversations as a Window Into Cognitive Impairment" by Gabriela Meade, PhD, CCC-SLP, and Hugo Botha, MBChB. Published online June 15, 2026. doi: 10.1001/jamaneurol.2026.1863.

010

JAMA Neurology @jamaneurology.com · 19/06/2026

Among adult #Ebola survivors, neurological symptoms such as memory loss, headaches, and depression remained common even 7 years post-infection, although most improved over time. ja.ma/4oycleA

JAMA Neurology: 'Neurological Manifestations in Adult Survivors Ebola Virus Disease'. Figure 3 presents four line graphs of GNE and CNS scores over 100 months, comparing Ebola survivors and contacts, grouped by age (<40 vs. ≥40). Scores vary for both groups.

010

JAMA Neurology @jamaneurology.com · 18/06/2026

010

JAMA Neurology @jamaneurology.com · 16/06/2026

Flow diagram showing an acoustic processing pipeline for patient-physician interactions. Acoustic noise, patient, and physician speech combine into raw recordings. These are windowed, features extracted, fed into an XGBoost model (represented as a tree), and output segment/recording-level predictions.

010

JAMA Neurology @jamaneurology.com · 16/06/2026

Among adult #Ebola survivors, neurological symptoms such as memory loss, headaches, and depression remained common even 7 years post-infection, although most improved over time. ja.ma/3S9IQ72

JAMA Neurology: Neurological Manifestations in Adult Survivors Ebola Virus Disease. Four graphs display longitudinal GNE & CNS scores over 100 months for Ebola survivors & contacts, separated by age (<40, ≥40) at enrollment. Scores generally decline or stabilize over time.

000

JAMA Neurology @jamaneurology.com · 15/06/2026

Randomized clinical trial indicates middle meningeal artery embolization with n-butyl cyanoacrylate plus standard care reduced #SubduralHematoma recurrence and need for surgery vs standard care alone, with comparable safety profile. ja.ma/3S25VbG

RCT results on Middle Meningeal Artery Embolization (MMAE) for chronic subdural hematoma. 376 patients (mean age 70) were randomized. A graph shows the MMAE group had a significantly lower failure probability (11.6%) compared to the standard care group (22.1%) over 183 days.

010

JAMA Neurology @jamaneurology.com · 14/06/2026

Integrating genetic and pathological data increased diagnostic accuracy and identified ancestry-related differences in #ParkinsonDisease, supporting biologically informed diagnostic tools and future pathology-targeted therapeutic trials. ja.ma/4go5uSS

Kaplan-Meier survival curve showing survival probability over 40 years for individuals with GBA1, LRRK2 variants, and those without. LRRK2 variants show higher survival probability over time compared to GBA1 PD risk, GBA1 GD-causing, and no variant groups.

000

JAMA Neurology @jamaneurology.com · 13/06/2026

Among adult #Ebola survivors, neurological symptoms such as memory loss, headaches, and depression remained common even 7 years post-infection, although most improved over time. ja.ma/4aNfy4i

Figure 3. Line graphs from JAMA Neurology show GNE and CNS scores over time (months since EVD symptoms) for Ebola survivors & contacts, stratified by age (<40, ≥40). Survivors' scores are initially higher & decrease, contacts' scores are low & stable.

111

JAMA Neurology @jamaneurology.com · 12/06/2026

A Kaplan-Meier survival curve shows survival probability vs. time (0-40 y) for different genetic variants. LRRK2 variants (blue line) show the highest survival, while GBA1 PD risk variants (dark gray) and No variant (light gray) show the lowest. A table below shows the number at risk for each group over time.

000

JAMA Neurology @jamaneurology.com · 10/06/2026

Among adult #Ebola survivors, neurological symptoms such as memory loss, headaches, and depression remained common even 7 years post-infection, although most improved over time. ja.ma/4fAUi5h

JAMA Neurology Figure 3: Four line graphs show longitudinal General Neurological Examination (GNE) and Central Nervous System (CNS) scores over 100 months post-Ebola symptoms for survivors & contacts, grouped by age (<40, ≥40). Scores typically stabilize or decrease over time.

121

JAMA Neurology @jamaneurology.com · 10/06/2026

Self-reported seizure durations in a large outpatient sample were often longer than laboratory-recorded values, with 90% of seizures lasting ≤4 minutes and substantial variation by seizure type and age group in #Epilepsy. ja.ma/3SvgmVa

Kaplan-Meier survival curve showing survival probability over 40 years for individuals with GBA1 PD risk, GBA1 GD-causing, LRRK2, or no variants. LRRK2 variants have the highest survival probability, GBA1 variants the lowest. A 'No. at risk' table is included.

000

JAMA Neurology @jamaneurology.com · 10/06/2026

Kaplan-Meier curve for GBA1, LRRK2 variant, & no variant groups. Y-axis: Survival probability, X-axis: Time (years). LRRK2 variants show highest survival; GBA1 GD-causing variants show lowest. A table below lists number at risk for each group over 40 years.

000

JAMA Neurology @jamaneurology.com · 09/06/2026

A reperfusion-guided systolic blood pressure strategy improved functional outcomes and reduced hemorrhagic transformation for patients with acute #Stroke after endovascular therapy compared with guideline-recommended management. ja.ma/4fzbvfs

JAMA Neurology study on personalized BP targeting after stroke. 440 patients (207M/233F, avg 75y) randomized. Intervention group (215 patients) had targeted BP, control (225 patients) standard care. Intervention group showed significantly better functional outcomes (60% vs 47%).

000

JAMA Neurology @jamaneurology.com · 09/06/2026

Among patients with acute ischemic #stroke due to large-vessel occlusion, standard-dose tenecteplase resulted in greater early reperfusion vs low-dose #alteplase, with comparable functional and safety outcomes. ja.ma/4vAqp9R

JAMA Neurology RCT: Tenecteplase vs Alteplase for stroke. In 218 adults, Tenecteplase (10.3% reperfusion) showed higher early substantial reperfusion vs Alteplase (3.6%). Bar chart illustrates findings. Study from 18 hospitals in Japan.

000